基石药业（苏州）有限公司 CSTONE PHARMACEUTICALS
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CStone announces first patient dosed in China for Phase I/II registrational bridging trial of avapritinib in advanced GIST 2019-08-26 11:21
CStone announces data from trials of CS1001, CS1002 and CS1003 to be released for the first time at 2019 CSCO Annual Meeting 2019-08-23 11:26
CStone completes registration filing for the Phase I trial of CDK4/6 inhibitor CS3002 in Australia and will soon initiate the study 2019-08-23 11:20
CStone submits an abstract on CS1001-201 trial to 2019 ASH Annual Meeting 2019-08-20 10:18
Abstract on CStone's CS1001-101 trial accepted for poster presentation at ESMO 2019 Annual Congress 2019-08-19 13:50
CStone Pharmaceuticals Reports First Half 2019 Financial Results 2019-08-15 15:31
CStone announces first patient dosed in China with BLU-667 for the global Phase I registrational study 2019-08-13 12:21
CStone to Build Global R&D Headquarters and Industrialization Base in the Suzhou Industrial Park 2019-08-07 14:47
CStone receives approval in China to initiate ivosidenib Phase I bridging registrational study for the treatment of IDH1 mutant relapsed or refractory AML 2019-07-22 12:17
CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST 2019-07-10 10:23
CStone and Bayer announce global collaboration to evaluate PD-L1 monoclonal antibody CS1001 in combination with regorafenib 2019-06-10 09:30
CStone received approval to initiate clinical development in China of CS1001 and BLU-554 (CS3008) in combination therapy for HCC 2019-06-05 19:56
CStone submits new drug application for TIBSOVO(R) in Taiwan for the treatment of relapsed/refractory AML 2019-06-03 11:45
Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO (ivosidenib) Achieved its Primary Endpoint 2019-05-23 18:36
CStone and Numab announce exclusive regional licensing agreement for ND021, a multi-functional drug candidate and potential next-generation immunotherapy 2019-05-02 11:05
First patient dosed in Phase III GEMSTONE-303 study for CS1001 in combination with chemotherapy in first-line gastric adenocarcinoma and gastro-esophageal junction adenocarcinoma 2019-04-16 16:58
CStone received IND approval in China for avapritinib Phase I/II bridging registrational study in patients with advanced gastrointestinal stromal tumors 2019-04-15 14:32
CStone Pharmaceuticals presented poster of pre-clinical result for CS1003 at AACR 2019-04-04 23:44
CStone appoints three distinguished oncology leaders Drs. Paul A. Bunn, Jr., Elizabeth M. Jaffee and Richard S. Finn to its Scientific Advisory Board 2019-03-25 15:14
CStone receives approval in China to initiate Phase 1 clinical trial for RET inhibitor BLU-667 (CS3009) 2019-03-21 21:32
1 4 5 6 7 8